Article
What are the current therapeutic options to treat corneal neovascularization?
Search Medline for
Authors
Published: | September 22, 2004 |
---|
Outline
Text
Objective
To provide an up to-date review on the current therapeutic options against corneal neovascularization.
Methods
A comprehensive literature search was performed for antiangiogenic therapeutic strategies available at the cornea. Therapeutic options were divided into angiostatic, angioregressive and angioocclusive approaches.
Results
Angiostatic options include indirect antiangiogenic agents such as topical steroids or cyclosporine A and also novel direct antiangiogenic agents. The latter are now mainly in phase 2 and 3 clinical trials for cancer and AMD patients (VEGF Trap, Macugen etc.). Angioregressive strategies have not yet left the preclinical experimental state, but could e.g. be based on a combination of a TIE 2 receptor agonist and VEGF blockade. Angioocclusive therapies include cautery of established large vessels or photodynamic therapy at the cornea.
Conclusions
A wide array of novel angiostatic (pharmacologic) agents will be available in the near future, either topically or as a systemic formulation, to treat corneal neovascularization.